Clinical trials: Infusions, Intravenous
Postoperative Pain, Renal Transplantation
Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy
Background: Administration of morphine as boluses or via a patient controlled analgesic device (PCA) has been the standard practice for donors after nephrectomy.
- Conditions
- Postoperative Pain, Renal Transplantation, Morphine Adverse Reaction
- Trial name
- NCT04052867
- Testing
- Lignocaine, Normal saline
- Where
- Malaysia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Laparoscopic Hysterectomy, Magnesium Sulfate
Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases
In our study, it was aimed to show the contribution of intraoperative intravenous magnesium sulfate administration to peroperative opioid consumption and postoperative analgesia.
- Conditions
- Laparoscopic Hysterectomy, Magnesium Sulfate, General Anesthesia
- Trial name
- MgSO4 (NCT05826119)
- Testing
- magnesium sulfate group
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ondokuz Mayıs University
Aspergillus Infections, Candida Infections
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
- Conditions
- Aspergillus Infections, Candida Infections, Fungal Infections
- Trial name
- NCT02631954
- Testing
- Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects
This study is primarily to evaluate the single dose pharmacokinetics of CP-751,871 and its effect on QT interval prolongation.
- Trial name
- NCT00926263
- Testing
- CP-751,871, CP-751,871, moxifloxacin, saline
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Thrombosis, Acute Coronary Syndrome
Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion
Primary objective: To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests Secondary objectives: To evaluate the pharmacokinetics and…
- Conditions
- Thrombosis, Acute Coronary Syndrome, Myocardial Infarction, Stroke
- Trial name
- PR-15/01 (NCT01042964)
- Testing
- revacept (PR-15)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AdvanceCor GmbH
Healthy Subjects
Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
A Dose Escalating Study of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
- Trial name
- NCT03384290
- Testing
- PRS-060
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pieris Australia Pty Ltd
Healthy Volunteers
A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers
The purpose of the phase 1, GTO-003 clinical study is to determine the safety and pharmacokinetics of a single dose of a new drug called GC4711 when given as an oral capsule.
- Trial name
- NCT03099824
- Testing
- GC4711 Oral Capsule G-101, IV GC4419, GC4711 Oral Capsule G-111
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Safety, Tolerability
Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after aSingle Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly(=65 years)…
- Conditions
- Safety, Tolerability, Pharmacokinetics, Sedation
- Trial name
- AZD3043 (NCT01086813)
- Testing
- AZD3043
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Heathly Subjects
Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects
1. Part 1 Randimization, Double blinded, Placebo controlled, Dose escalation(10mg, 20mg, 40mg) of MIT-001 SC or IV single administration to evaluate safety, tolerability and PK in healthy adult. 2.
- Trial name
- NCT05389696
- Testing
- Single subcutaneous administration and Blood collection, Single subcutaneous administration and then IV injection., MIT-001 20mg and 40mg_Multiple administration
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MitoImmune Therapeutics
Healthy
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers
A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.
- Trial name
- NCT03500627
- Testing
- OP-101
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Orpheris, Inc.
Healthy Elderly Subjects
Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects
It is a single-center, open-label, dose-finding, Phase I clinical study evaluating the pharmacokinetics, pharmacodynamics, and safety characteristics of HSK3486 in healthy elderly subjects.
- Trial name
- NCT04197661
- Testing
- HSK3486
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects
This is a randomized, placebo controlled, single dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-E2 in healthy male subjects.
- Trial name
- GX-E2-P1 (NCT02291991)
- Testing
- GX-E2
- Where
- South Korea
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Skeletal Muscle Relaxation
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HRS-9190 in Healthy Adults
This study is divided into two parts. The first part adopts a single-center, randomized, single-blind, placebo-controlled dose escalation trial design to investigate the safety, tolerability, pharmacokinetics (PK), and effects on…
- Trial name
- NCT07142850
- Testing
- HRS-9190
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Infection
A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of metronidazole following single and multiple intravenous infusion in healthy Japanese adult subjects.
- Trial name
- NCT01407016
- Testing
- metronidazole IV 500 mg
- Where
- Japan
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
The purpose of this study is to gain an understanding of how the experimental anti-cancer drug, rigosertib, is metabolized in the body and excreted in the urine and feces after it is given as an intravenous infusion.
- Trial name
- NCT02030639
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
Bariatric Surgery, Lidocaine
Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy
Although laparoscopic (LAP) bariatric surgery is minimally invasive. Following any laparoscopic procedure, patients typically experience the peak of postoperative pain within the first 24 hours.
- Conditions
- Bariatric Surgery, Lidocaine, Dexmedetomidine
- Trial name
- NCT07327905
- Testing
- intravenous lidocaine, intravenous dexmedetomidine
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Inflammatory Bowel Diseases
First Time in Human Study of Intravenous Interleukin-18 Antibody
GSK1070806 is a humanised monoclonal antibody that blocks a protein present in the body called Interleukin-18. The main purpose of this study is to test GSK1070806 in healthy and obese male subjects with normal immune systems to…
- Trial name
- A18110040 (NCT01035645)
- Testing
- GSK1070806
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous administration of SHR-1707 in healthy young adult and elderly subjects.
- Trial name
- NCT04973189
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-9596 in patients with cancer and inflammation
- Trial name
- NCT01089998
- Testing
- BAY86-9596, Fludeoxyglucose (18F)-IBA
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.